Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Akebia Therapeutics to announce earnings of ($0.03) per share and revenue of $48.8520 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). Akebia Therapeutics had a negative return on equity of 62.72% and a negative net margin of 8.83%.The company had revenue of $53.54 million for the quarter, compared to analysts’ expectations of $51.67 million. On average, analysts expect Akebia Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Akebia Therapeutics Trading Down 0.8%
Shares of AKBA stock opened at $1.26 on Thursday. The company has a market capitalization of $338.01 million, a price-to-earnings ratio of -15.75 and a beta of 0.23. The company has a current ratio of 1.40, a quick ratio of 1.33 and a debt-to-equity ratio of 1.33. The firm has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.27. Akebia Therapeutics has a twelve month low of $0.82 and a twelve month high of $3.81.
Insider Activity at Akebia Therapeutics
Institutional Investors Weigh In On Akebia Therapeutics
A number of institutional investors have recently added to or reduced their stakes in AKBA. UBS Group AG raised its holdings in shares of Akebia Therapeutics by 470.2% in the 3rd quarter. UBS Group AG now owns 3,646,233 shares of the biopharmaceutical company’s stock worth $9,954,000 after purchasing an additional 3,006,771 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Akebia Therapeutics by 166.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,706,437 shares of the biopharmaceutical company’s stock valued at $7,577,000 after purchasing an additional 2,938,624 shares in the last quarter. MPM Bioimpact LLC purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter worth about $10,516,000. Invesco Ltd. grew its holdings in shares of Akebia Therapeutics by 528.1% during the 3rd quarter. Invesco Ltd. now owns 2,400,757 shares of the biopharmaceutical company’s stock worth $6,554,000 after purchasing an additional 2,018,547 shares during the period. Finally, State Street Corp increased its position in Akebia Therapeutics by 15.6% during the 4th quarter. State Street Corp now owns 13,687,561 shares of the biopharmaceutical company’s stock worth $22,037,000 after purchasing an additional 1,842,792 shares in the last quarter. Hedge funds and other institutional investors own 33.92% of the company’s stock.
Analysts Set New Price Targets
AKBA has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Zacks Research upgraded shares of Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Akebia Therapeutics in a research report on Wednesday, May 6th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Akebia Therapeutics in a research note on Wednesday, July 1st. Finally, BTIG Research reiterated a “buy” rating and issued a $4.00 price target on shares of Akebia Therapeutics in a report on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.67.
Read Our Latest Stock Report on AKBA
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.
Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.
Read More
- Five stocks we like better than Akebia Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
